Cannabidiol in Anxiety and Sleep: A Large Case Series.

@article{Shannon2019CannabidiolIA,
  title={Cannabidiol in Anxiety and Sleep: A Large Case Series.},
  author={Scott M. Shannon and Nicole Lewis and Hea Eul Lee and Shannon Hughes},
  journal={The Permanente journal},
  year={2019},
  volume={23},
  pages={
          18-041
        }
}
CONTEXT Cannabidiol (CBD) is one of many cannabinoid compounds found in cannabis. [] Key MethodDESIGN A large retrospective case series at a psychiatric clinic involving clinical application of CBD for anxiety and sleep complaints as an adjunct to usual treatment. The retrospective chart review included monthly documentation of anxiety and sleep quality in 103 adult patients. MAIN OUTCOME MEASURES Sleep and anxiety scores, using validated instruments, at baseline and after CBD treatment.

Figures and Tables from this paper

Use of Cannabidiol for the Treatment of Anxiety: A Short Synthesis of Pre-Clinical and Clinical Evidence.

Early evidence from human trials using both healthy volunteers and individuals with social anxiety disorder, suggests that CBD may have anxiolytic effects, and future research is warranted to determine the efficacy of CBD in other anxiety disorders, establish appropriate doses, and determine its long-term efficacy.

Cannabinoids and Mental Health, Part 2: The Search for Clinical Applications.

  • A. Penn
  • Medicine, Psychology
    Journal of psychosocial nursing and mental health services
  • 2019
Until additional, well-designed studies that examine the more common practice of lower doses of CBD are performed, a harm-reduction, patient-centered, empiric approach is encouraged to optimize symptom reduction while at the same time avoiding the known risks of cannabis.

Use of cannabidiol in anxiety and anxiety-related disorders.

Cannabidiol treatment in an adolescent with multiple substance abuse, social anxiety and depression

The patient improved regarding depressive as well as anxiety symptoms including simple phobias and symptoms of paranoia and dissociation, and the patient quit abusing illegal drugs including THC without showing withdrawal symptoms.

Cannabinoid Regulation of Fear and Anxiety: an Update

Based on this preclinical evidence, larger-scale placebo-controlled clinical studies are warranted to investigate the effects of cannabidiol in particular as an adjunct to psychological therapy or medication to determine its potential utility for treating anxiety-related disorders in the future.

The therapeutic role of Cannabidiol in mental health: a systematic review

CBD and CBD-containing compounds such as nabiximols were helpful in alleviating symptoms of cannabis-related disorders, schizophrenia, social anxiety disorder, and comorbidities of ASD, and ADHD with moderate recommendation, however, there is weaker evidence for insomnia, anxiety, bipolar disorder, posttraumatic stress disorder and Tourette syndrome.
...

References

SHOWING 1-10 OF 29 REFERENCES

Cannabidiol in Humans—The Quest for Therapeutic Targets

Preliminary clinical trials suggest that high-dose oral CBD may exert a therapeutic effect for social anxiety disorder, insomnia and epilepsy, but also that it may cause mental sedation.

Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation?

Findings suggest promising treatment effects and potentially overlapping mechanisms of action for CBD in these disorders and indicate the need for further systematic investigation of the viability of CBD as a psychiatric pharmacotherapy.

Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders

CBD bears investigation in epilepsy and other neuropsychiatric disorders, including anxiety, schizophrenia, addiction, and neonatal hypoxic‐ischemic encephalopathy, however, data from well‐powered double‐blind randomized, controlled studies on the efficacy of pure CBD for any disorder is lacking.

An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies

The often described favorable safety profile of CBD in humans was confirmed and extended by the reviewed research, and some important toxicological parameters are yet to be studied, for example, if CBD has an effect on hormones.

Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients

The increase in anxiety induced by the SPST on subjects with SAD was reduced with the use of CBD, resulting in a similar response as the HC, and no significant differences were observed between CBD and HC in SSPS-N scores or in the cognitive impairment, discomfort, and alert factors of VAMS.

Effects of ipsapirone and cannabidiol on human experimental anxiety

The results suggest that ipsapirone and CBD have anxiolytic properties in human volunteers submitted to a stressful situation.

Cannabis in painful HIV-associated sensory neuropathy

Smoked cannabis was well tolerated and effectively relieved chronic neuropathic pain from HIV-associated sensory neuropathy and the findings are comparable to oral drugs used for chronic Neuropathic pain.

Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It's Been …

Physicians need to be educated on the history, pharmacology, clinical indications, and proper clinical use of cannabis, as patients will inevitably inquire about it for many diseases, including chronic pain and headache disorders for which there is some intriguing supportive evidence.

Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life

The results confirmed that the acute administration of CBD induced anxiolytic effects with a dose-dependent inverted U-shaped curve in healthy subjects, since the subjective anxiety measures were reduced with CBD 300 mg, but not with CBD 100 and 900 mg, in the post-speech phase.

Trial of Cannabidiol for Drug‐Resistant Seizures in the Dravet Syndrome

Among patients with the Dravet syndrome, cannabidiol resulted in a greater reduction in convulsive‐seizure frequency than placebo and was associated with higher rates of adverse events.